Cabozantinib
id:
cabozantinib-180-17340934
title:
Cabozantinib
text:
Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. It was discovered and developed by Exelixis Inc. In November 2012, cabozantinib in its capsule formulation was approved by the US Food and Drug Administration (FDA) under the name Cometriq for tr
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Cabozantinib
date created:
2011-05-18T11:34:37Z
date modified:
2024-09-05T14:00:43Z
main entity:
{"identifier":"Q795057","url":"https://www.wikidata.org/entity/Q795057"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/f/f8/Cabozantinib.svg","width":512,"height":221}
fields total:
13
integrity:
16